Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Judith Trotman, FRACP, Christian Buske, MD, Alessandra Tedeschi, MD, Jeffrey V. Matous, MD, David MacDonald, MD, Constantine Tam, MBBS, Olivier Tournilhac, MD PhD, Shuo Ma, MD PhD, Steven P. Treon, MD PhD, Albert Oriol, Jerry Ping, PhD, Eva M. Briso, PhD, Israel Arango-Hisijara, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-133916

Published: 2020

Journal Articles

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Constantine Tam, MBBS, MD, Mary Ann Anderson, MBBS, David S. Ritchie, MDPhD, E. Henry Januszewicz, MBBS, Dennis Carney, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2015) 126 (23): 2939.

https://doi.org/10.1182/blood.V126.23.2939.2939

Published: 2015

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 832.

https://doi.org/10.1182/blood.V126.23.832.832

Published: 2015

Journal Articles

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

Blood (2015) 126 (23): 833.

https://doi.org/10.1182/blood.V126.23.833.833

Published: 2015

Journal Articles

ZAP70 Expression by Immunohistochemistry Correlates with IgVH Mutation Status in Chronic Lymphocytic Leukemia and Predicts Time to Progression, but Survival Is Decreased in p53-Positive CLL, Regardless of ZAP70 Expression.

Ellen J. Schlette, MD, Constantine Tam, MBBS, Joan Admirand, MD, William Wierda, MD, Susan O’Brien, MD, Susan Lerner, MS, Michael J. Keating, MBBS

Blood (2007) 110 (11): 3083.

https://doi.org/10.1182/blood.V110.11.3083.3083

Published: 2007

Journal Articles

The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience.

Apostolia-Maria Tsimberidou, MD, PhD, Constantine Tam, MBBS, William G. Wierda, MD, PhD, Susan O’Brien, MD, Susan Lerner, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS

Blood (2007) 110 (11): 2078.

https://doi.org/10.1182/blood.V110.11.2078.2078

Published: 2007

NARROW

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

ZAP70 Expression by Immunohistochemistry Correlates with IgVH Mutation Status in Chronic Lymphocytic Leukemia and Predicts Time to Progression, but Survival Is Decreased in p53-Positive CLL, Regardless of ZAP70 Expression.

The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience.

Email alerts

ASH Publications

American Society of Hematology

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

ZAP70 Expression by Immunohistochemistry Correlates with IgVH Mutation Status in Chronic Lymphocytic Leukemia and Predicts Time to Progression, but Survival Is Decreased in p53-Positive CLL, Regardless of ZAP70 Expression.

The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only